Next-generation personalized drug discovery: The tripeptide GHK hits center stage in chronic obstructive pulmonary disease.

ABSTRACT: Chronic lung diseases (CLDs), including chronic obstructive pulmonary disease (COPD), are the second leading cause of death worldwide. The first report of database-driven drug discovery in carefully phenotyped COPD specimens has now been published in Genome Medicine, combining gene expression data in defined emphysematous areas with connectivity-map-based compound discovery. This joint effort may lead the way to novel and potentially more efficient concepts of personalized drug discovery for COPD in particular, and CLD in general.See research article http://genomemedicine.com/content/4/8/67/abstract